Six Steps to Better Cancer Care in Europe
A report published yesterday provides recommendations for combating the “significant inequalities” affecting access to quality cancer care in Europe.
A report published yesterday provides recommendations for combating the “significant inequalities” affecting access to quality cancer care in Europe.
Cancer is still the second leading cause of death in the European Union, responsible for around 1.3 million of all 5 million deaths per year.
Based on a review of colorectal, lung and prostate cancer care in France, Germany, Poland and Sweden, the “Access to high-quality oncology care across Europe” report, commissioned by Janssen and based on research by the Swedish Institute for Health Economics (IHE), offers six initial policy recommendations. It states a need for:
1. cost-effective allocation of provision and spending;
2. improved funding and resourcing;
3. incentivization of innovative research, including the design of reimbursement systems, reward of innovations in cancer care, and the development of new payment schemes;
4. better integrated and organized cancer care system;
5. collation of data on resource use and outcomes to monitor standards and regional differences; and
6. more recognition of the quality of life as an outcome measure for the individual and society.
The report’s co-author, Bengt Jonsson, of the Stockholm School of Economics, highlighted that “France has the quickest and most extensive uptake of new cancer drugs followed by Germany, while here in Sweden we are falling behind Germany and France. Poland meanwhile, falls significantly behind all three.”
For more information: http://www.prnewswire.co.uk/news-releases/253705791.html.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
